trending Market Intelligence /marketintelligence/en/news-insights/trending/927cot9kxkaayoyh5q9qrg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA approves Shire's hemophilia A treatment in pediatrics

Power Forecast Briefing: Tight Reserves to Benefit Conventional Gas Generation versus Renewable Energy

State of the Market: Mining Q2-2019

Mining Exploration Insights

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency


US FDA approves Shire's hemophilia A treatment in pediatrics

The U.S. FDA approved Shire PLC's Adynovate for the treatment of hemophilia A in pediatric patients under 12 years of age.

The drug was first approved for adults with the genetic blood disorder in November 2015.

The regulator also approved the use of the drug in adult and pediatric patients undergoing surgery.